Table 4.
Summary of most frequent adverse events by organ system, number of dogs affected
| Category of adverse events | High dose, N = 66 Number of dogs (dogs with likely treatment relation) | Low dose, N = 61 Number of dogs (dogs with likely treatment relation) | Significancea, high vs. low-dose group (dogs with likely treatment relation) |
|---|---|---|---|
| Any | 57 (39) | 50 (25) | p = 0.497 (p = 0.041) |
| Central nervous systemb | 48 (33a) | 32 (19a) | p = 0.018 (p = 0.031) |
| Gastro-intestinal system | 32 (8) | 25 (2) | p = 0.396 (p = 0.065) |
| Musculoskeletal system | 12 (10) | 8 (3) | p = 0.443 (p = 0.057) |
| Respiratory system | 7 (4) | 8 (4) | p = 0.662 (p = 0.908) |
| General | 5 (2) | 5 (2) | p = 0.897 (p = 0.936) |
| Urogenital tract | 4 (1) | 5 (1) | p = 0.639 (p = 0.956) |
| Other systems | 14 (10) | 15 (3) | p = 0.650 (p = 0.057) |
aBased on the two-sided chi-square test for the equality of proportions from two independent samples
bMainly seen during first weeks of treatment